NCT02489292 - Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Urea Cycle Disorders

Interventions

BIOLOGICAL

HepaStem

HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight

Trial Locations (6)

1200

Cliniques Universitaires Saint-Luc, Brussels

29011

Hospital Materno Infantil de Málaga, Málaga

59037

Hôpital Jeanne de Flandre, CHRU Lille, Lille

Unknown

Instytut - Pomnik Centrum Zdrowia Dziecka, Warsaw

06010

Hospital Materno Infatil de Badajoz, Badajoz

08035

Hospital Universitari Vall d'Hebron de Barcelona, Barcelona